Streetbeat News

Products Services

DMTTF

UK-based biotech firm Small Pharma Inc. (OTCQB:DMTTF) reported a net loss of $17.2 million for the fiscal year ended Feb. 28, 2023, compared to $16.7 million in FY2022. The company's cash reserves decreased to $13.9 million from $30.6 million over the same period. Small Pharma is implementing a cost-cutting strategy to reduce its annual cash burn and extend its runway to Q4 2024. The company's DMT-related compounds, SPL026 and SPL028, have shown progress in clinical trials, with positive outcomes in a Phase 2a trial for SPL026 and preliminary findings validating the target drug profile for SPL028.

Portfolio Pulse from Lara Goldstein

June 29, 2023 | 6:55 pm

BMRN

The FDA has approved BioMarin's ROCTAVIAN gene therapy for adults with severe Hemophilia A. ROCTAVIAN is a one-time, single-dose treatment and its approval was based on durability, efficacy, and safety results from the largest and longest Phase 3 study for a gene therapy for Hemophilia. Majority of patients continued to respond to ROCTAVIAN treatment over 3 years.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 6:38 pm

SHOP

YCBD

cbdMD, a leading cannabidiol (CBD) brand, has announced its migration to Shopify for its e-commerce needs. This move is expected to enhance the company's online sales capabilities.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 6:27 pm

F

GM

TSLA

Electrify America is integrating Tesla's North American Charging Standard (NACS) connector into its fast charging networks in the U.S. and Canada. This move is in response to automakers like General Motors and Ford adopting the NACS standard. The company aims to have the NACS connector available at all existing and future charging stations by 2025.

Portfolio Pulse from Benzinga EV Insights

June 29, 2023 | 6:15 pm

RNXT

RenovoRx Inc (NASDAQ:RNXT) presented new data from its Phase 3 TIGeR-PaC study of RenovoGem in advanced pancreatic cancer at the 2023 ESMO World Congress on Gastrointestinal Cancer. The interim analysis showed an eight-month median progression-free survival (PFS) benefit for patients treated with RenovoGem compared to standard care. The TIGeR-PaC Data Monitoring Committee found the interim data promising and recommended the continuation of the trial. RNXT shares are up 8.93% at $2.44.

Portfolio Pulse from Vandana Singh

June 29, 2023 | 6:09 pm

DLTR

Dollar Tree, a US-based discount variety store, has announced plans to raise prices up to $5, moving away from its traditional $1 price point. This move is seen as a response to inflationary pressures and supply chain disruptions.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 5:56 pm

HON

HTHIY

KMB

LPL

MMM

PCRFY

WHR

Due to the increasing frequency and severity of wildfires, particularly in Canada, air quality in major US cities is deteriorating. This has led to a rise in the use of face masks and air purifiers. Companies such as 3M, Honeywell, and Kimberly-Clark, which manufacture N95 masks, and Whirlpool Corporation, LG, Hitachi, and Panasonic, which produce air purifiers and air conditioning units, could benefit from this trend.

Portfolio Pulse from Natan Ponieman

June 29, 2023 | 5:56 pm

MA

Mastercard Inc (NYSE:MA) has unveiled its Mastercard Multi-Token Network (MTN), a blockchain-based platform aimed at enabling secure, scalable, and interoperable transactions within the digital asset and blockchain ecosystems. The beta version of MTN will be available in the UK during the summer. The platform will serve as an experimental platform for developing live pilot applications in collaboration with financial institutions, fintech companies, and central banks. The initial phase of applications will be powered by tokenized bank deposits.

Portfolio Pulse from Murtuza Merchant

June 29, 2023 | 5:43 pm

AZN

BAYRY

AstraZeneca has released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi plus Imjudo in unresectable hepatocellular carcinoma patients. The data shows that the treatment reduced the risk of death by 22% compared to Bayer's Nexavar. The safety profile was consistent with known profiles and no new safety signals were observed. AstraZeneca's shares are down 0.16% at $70.85.

Portfolio Pulse from Vandana Singh

June 29, 2023 | 5:41 pm

MRNA

Moderna has initiated a rolling New Drug Submission to Health Canada for its updated COVID-19 vaccine, SPIKEVAX® XBB.1.5, targeting the omicron subvariant XBB.1.5 of SARS-CoV-2. This follows Moderna's submission to the U.S. FDA for authorization. The company is prepared to deliver the updated vaccines in time for the fall 2023 vaccination season.

Portfolio Pulse from Happy Mohamed

June 29, 2023 | 5:40 pm